Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab

E. Montagna, G. Cancello, D. D'Agostino, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, A. Accurso, S. De Placido, M. De Laurentiis

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Several analyses suggest an increase of brain metastases in HER2 over-expressing breast cancers treated with trastuzumab as compared to historical series of unselected patients. Patients and methods We analyzed the incidence of central nervous system (CNS) metastases in 78 patients with HER2 over-expressing breast cancer treated with trastuzumab between July 2000 and June 2006 at the Oncology Department of University Federico II in Naples. We also characterized and compared patients with and without CNS involvement. Results The median follow-up was 35.3 months (95%CI 26.3-44); median overall survival was 56 months (95%CIs 46-nr); 5 patients showed CNS involvement before trastuzumab therapy while 31 developed CNS metastases during trastuzumab treatment. The median overall survival after CNS metastases was 25.4 months (95%CIs 15.2-nr); patients with CNS lesions showed worse overall survival than patients without CNS lesions (39.1 vs. 75 months, p = 0.005). Conclusion CNS metastases are common events in patients with metastatic HER2 over-expressing breast cancer treated with trastuzumab; the impact on survival is detrimental even if survival after CNS metastases is longer than historical reports. Appropriate investigation of the role of CNS imaging screening and the prophylactic treatment strategies for CNS represents a priority research in this setting.

Original languageEnglish
Pages (from-to)275-280
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume63
Issue number2
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Neurology
Central Nervous System
Breast Neoplasms
Neoplasm Metastasis
Survival
Trastuzumab
Oncology
Brain
Screening
Therapeutics
Imaging techniques

Keywords

  • Breast cancer
  • Central nervous system
  • CNS metastases
  • HER2
  • Survival
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. / Montagna, E.; Cancello, G.; D'Agostino, D.; Lauria, R.; Forestieri, V.; Esposito, A.; Silvestro, L.; Accurso, A.; De Placido, S.; De Laurentiis, M.

In: Cancer Chemotherapy and Pharmacology, Vol. 63, No. 2, 01.2009, p. 275-280.

Research output: Contribution to journalArticle

@article{e27c9b2032934deab8649684bc1c0c73,
title = "Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab",
abstract = "Background Several analyses suggest an increase of brain metastases in HER2 over-expressing breast cancers treated with trastuzumab as compared to historical series of unselected patients. Patients and methods We analyzed the incidence of central nervous system (CNS) metastases in 78 patients with HER2 over-expressing breast cancer treated with trastuzumab between July 2000 and June 2006 at the Oncology Department of University Federico II in Naples. We also characterized and compared patients with and without CNS involvement. Results The median follow-up was 35.3 months (95{\%}CI 26.3-44); median overall survival was 56 months (95{\%}CIs 46-nr); 5 patients showed CNS involvement before trastuzumab therapy while 31 developed CNS metastases during trastuzumab treatment. The median overall survival after CNS metastases was 25.4 months (95{\%}CIs 15.2-nr); patients with CNS lesions showed worse overall survival than patients without CNS lesions (39.1 vs. 75 months, p = 0.005). Conclusion CNS metastases are common events in patients with metastatic HER2 over-expressing breast cancer treated with trastuzumab; the impact on survival is detrimental even if survival after CNS metastases is longer than historical reports. Appropriate investigation of the role of CNS imaging screening and the prophylactic treatment strategies for CNS represents a priority research in this setting.",
keywords = "Breast cancer, Central nervous system, CNS metastases, HER2, Survival, Trastuzumab",
author = "E. Montagna and G. Cancello and D. D'Agostino and R. Lauria and V. Forestieri and A. Esposito and L. Silvestro and A. Accurso and {De Placido}, S. and {De Laurentiis}, M.",
year = "2009",
month = "1",
doi = "10.1007/s00280-008-0737-3",
language = "English",
volume = "63",
pages = "275--280",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab

AU - Montagna, E.

AU - Cancello, G.

AU - D'Agostino, D.

AU - Lauria, R.

AU - Forestieri, V.

AU - Esposito, A.

AU - Silvestro, L.

AU - Accurso, A.

AU - De Placido, S.

AU - De Laurentiis, M.

PY - 2009/1

Y1 - 2009/1

N2 - Background Several analyses suggest an increase of brain metastases in HER2 over-expressing breast cancers treated with trastuzumab as compared to historical series of unselected patients. Patients and methods We analyzed the incidence of central nervous system (CNS) metastases in 78 patients with HER2 over-expressing breast cancer treated with trastuzumab between July 2000 and June 2006 at the Oncology Department of University Federico II in Naples. We also characterized and compared patients with and without CNS involvement. Results The median follow-up was 35.3 months (95%CI 26.3-44); median overall survival was 56 months (95%CIs 46-nr); 5 patients showed CNS involvement before trastuzumab therapy while 31 developed CNS metastases during trastuzumab treatment. The median overall survival after CNS metastases was 25.4 months (95%CIs 15.2-nr); patients with CNS lesions showed worse overall survival than patients without CNS lesions (39.1 vs. 75 months, p = 0.005). Conclusion CNS metastases are common events in patients with metastatic HER2 over-expressing breast cancer treated with trastuzumab; the impact on survival is detrimental even if survival after CNS metastases is longer than historical reports. Appropriate investigation of the role of CNS imaging screening and the prophylactic treatment strategies for CNS represents a priority research in this setting.

AB - Background Several analyses suggest an increase of brain metastases in HER2 over-expressing breast cancers treated with trastuzumab as compared to historical series of unselected patients. Patients and methods We analyzed the incidence of central nervous system (CNS) metastases in 78 patients with HER2 over-expressing breast cancer treated with trastuzumab between July 2000 and June 2006 at the Oncology Department of University Federico II in Naples. We also characterized and compared patients with and without CNS involvement. Results The median follow-up was 35.3 months (95%CI 26.3-44); median overall survival was 56 months (95%CIs 46-nr); 5 patients showed CNS involvement before trastuzumab therapy while 31 developed CNS metastases during trastuzumab treatment. The median overall survival after CNS metastases was 25.4 months (95%CIs 15.2-nr); patients with CNS lesions showed worse overall survival than patients without CNS lesions (39.1 vs. 75 months, p = 0.005). Conclusion CNS metastases are common events in patients with metastatic HER2 over-expressing breast cancer treated with trastuzumab; the impact on survival is detrimental even if survival after CNS metastases is longer than historical reports. Appropriate investigation of the role of CNS imaging screening and the prophylactic treatment strategies for CNS represents a priority research in this setting.

KW - Breast cancer

KW - Central nervous system

KW - CNS metastases

KW - HER2

KW - Survival

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=57149125472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149125472&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0737-3

DO - 10.1007/s00280-008-0737-3

M3 - Article

C2 - 18379783

AN - SCOPUS:57149125472

VL - 63

SP - 275

EP - 280

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -